Colorectal Cancer Clinical Trial
— SONCHIMIOOfficial title:
Targeted Delivery of Chemotherapy With Ultrasound and Microbubbles
Verified date | January 2023 |
Source | University Hospital, Tours |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US waves engender a modulation of the permeability of biological barriers amplifying hence the extravasation of drugs and/or fluorescent markers through a process known as sonoporation. In such a way, the bioavailability of the therapeutic agent is augmented only in the area where US waves are focused. The objective now is to translate this therapeutic approach to the clinic by performing a feasibility study with the development of a therapy regime optimized for hepatic metastases of colorectal cancer. In order to demonstrate the clinical feasibility of the therapeutic approach based on ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal cancer treated with monoclonal antibodies in combination with chemotherapy.
Status | Completed |
Enrollment | 7 |
Est. completion date | September 30, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - patient with liver metastases from colorectal cancer; patient with minimum two liver metastases which satisfy all the following criteria: diameter between 10 and 35 mm; arterially enhancing liver metastases detected with contrast enhanced ultrasound (CEUS); measurable liver metastases with CT-scan (Acceptability of a patient with more than 4 metastases or a patient with an odd number of metastases = 2). - age = 18 years; - ECOG/OMS 0-1; - life expectancy of at least 12 weeks; - adequate bone marrow, liver and kidney function; - written informed consent obtained from subject; - subjects covered by or having the rights to social security; - bi-weekly chemotherapy regimen - neo-adjuvant standard chemotherapy or palliative standard chemotherapy (first or second metastatic line) following the recommendations in force (national thesaurus of digestive oncology - colorectal cancer chapter: Phelip JM, Benhaim L, Bouché O, Christou N, Desolneux G, Dupré A, Léonard D, Michel P, Penna C, Rousseaux B, Tougeron D, Tournigand C. "Cancer colorectal métastatique". Thésaurus National de Cancérologie Digestive, Janvier 2019, http://www.tncd.org). Exclusion Criteria: - Previous local treatment of selected liver metastases (radiofrequency, radioembolization, …); - Indication for local ablative therapy of selected liver metastasis (radiofrequency ablation or other validated hepatic-directed modality of treatment); - Previous malignancy other than colorectal adenocarcinoma within 3 years prior to the inclusion with the exception for curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical or breast cancer; - Known contraindication to the injection of Sonovue®, of Gadolinium, of iodated contrast agent; - contraindication to MRI or perfusion CT scan; - Patient under legal protection; - Pregnant or lactating woman, or woman with ability to procreate and without contraception; - Inclusion in another therapeutic trial - Uracilemia greater than or equal to 150ng/mL (suggestive of a complete DPD deficiency). - Presence of any material with potential interaction with ultrasound beam (metal, etc.) or healing tissue, and which cannot be bypassed |
Country | Name | City | State |
---|---|---|---|
France | Service d'Hépatogastro-entérologie CHRU de TOURS | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response for liver metastases | Objective response for liver metastases with spiral CT scan and defined as decrease of at least 30% in the longer diameter of each selected liver metastases | 2 months | |
Secondary | Safety | Safety based on National Cancer Institute (NCI), Common Terminology Criteria for Adverse events (CTCAE) | Day 3, Day 17, Day 32, Day 47 | |
Secondary | Tolerance | Tolerance based on National Cancer Institute (NCI), Common Terminology Criteria for Adverse events (CTCAE) | Day 3, Day 17, Day 32, Day 47 | |
Secondary | Maximum percent reduction in tumor density on CT scan | Maximum percent reduction in tumor density (Hounsfield units) from baseline | 2 months | |
Secondary | Maximum percent reduction in tumor density on MRI | Maximum percent reduction in tumor density from baseline | 2 months | |
Secondary | Assessment of tumor vascularity by Perfusion CT scan | Assessment of tumor vascularity with Perfusion CT scan | 2 months | |
Secondary | Assessment of tumor vascularity by MRI | Assessment of tumor vascularity with MRI | 2 months | |
Secondary | Assessment of tumor vascularity by Dynamic Contrast-Enhanced US (DCE-US) | Assessment of tumor vascularity with Dynamic Contrast-Enhanced US (DCE-US) | 2 months | |
Secondary | Dosage of antibody anti-VEGF or anti-EGFR | Measures of serum concentration of antibody anti-VEGF or anti-EGFR | Day1, Day 3, Day 15, Day 17, Day 32, Day 45 | |
Secondary | Dosage of antibody anti-VEGF or anti-EGFR by ELISA test | Pharmacokinetic of antibody anti-VEGF or anti-EGFR | Day1, Day 3, Day 15, Day 17, Day 32, Day 45 | |
Secondary | Dosage of cytokines | Dosage of cytokines | Day1, Day 3, Day 15, Day 17, Day 32, Day 45 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |